FDA Accepts BLA for Anifrolumab by AstraZeneca
The FDA has accepted the Biologics License Application for Anifrolumab, a treatment for systemic lupus erythematosus.
Asset / Drug
Drug and asset intelligence for Anifrolumab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.